Mesoporous nano-selenium, mesoporous nano-selenium drug loading system as well as preparation method and application of mesoporous nano-selenium drug loading system

Abstract

The invention discloses mesoporous nano-selenium, a mesoporous nano-selenium drug loading system as well as a preparation method and application of the mesoporous nano-selenium drug loading system. The preparation method of the mesoporous nano-selenium comprises the following steps: (1) dissolving a surfactant in water, then adding Zn, and uniformly stirring to obtain a mixed solution; (2) adding a Na2SeO3 solution and a VC solution into the mixed solution, and carrying out a stirring reaction; and (3) after the reaction is finished, separating the solid, adding the solid into ethanol, carrying out heating reflux for 20-30 hours, after the reflux is finished, taking the solid, and drying the solid to obtain the mesoporous nano-selenium. The preparation method of the mesoporous nano-selenium drug loading system comprises the following steps: adding mesoporous nano-selenium into a mixed solution containing EGCG and CAR, and stirring for 40-90 minutes; and after the stirring is finished, separating the solid to obtain the mesoporous nano-selenium drug loading system. According to the mesoporous nano-selenium and the mesoporous nano-selenium drug loading system disclosed by the invention, accurate treatment on pulmonary arterial hypertension can be realized by inhibiting excessive proliferation of smooth muscle cells and related cell signal channels.

Description

Technical Field

[0001] This invention relates to the field of nanomedicine technology, specifically to a mesoporous selenium nanoparticle, a mesoporous selenium nanoparticle drug-loaded system, its preparation method, and its application. Background Technology

[0002] Pulmonary arterial hypertension (PAH) is a rapidly progressing pulmonary vascular disease with a poor prognosis. Nanotechnology-based drug delivery systems are considered effective carriers for packaging drugs and genetic material, showing great potential in the treatment of respiratory diseases.

[0003] Traditionally, drug treatment for pulmonary hypertension (PAH) relies on the regulation of vascular tone, primarily targeting the prostacyclin (PGI2), endothelin (ET), and nitric oxide signaling pathways. These drugs only improve hemodynamics, do not cure the condition, and have serious side effects. The inability to deliver PAH-treating drugs directly to the disease site has been a major obstacle to improving patient outcomes and treatment efficacy. Aside from lung transplantation, there are currently no effective treatments for PAH; therefore, there is an urgent need to develop innovative therapies that can attenuate or even reverse PAH. Summary of the Invention

[0004] In order to overcome at least one of the technical problems existing in the prior art, the present invention first provides a mesoporous nano-selenium.

[0005] The technical problem to be solved by the present invention is achieved through the following technical solution:

[0006] A method for preparing mesoporous selenium nanoparticles, comprising the following steps:

[0007] (1) Dissolve the surfactant in water, then add Zn and stir until a mixture is obtained;

[0008] (2) Next, add Na2SeO3 solution and VC solution to the mixture and stir to react;

[0009] (3) After the reaction is complete, the solid is separated and added to ethanol and heated under reflux for 20-30 hours. After the reflux is complete, the solid is taken out and dried to obtain nanoparticles MSeNPs, i.e., the mesoporous nanoselenium.

[0010] The inventors were surprised to discover in numerous experiments that the mesoporous selenium nanoparticles prepared by the method described above have a certain inhibitory effect on the proliferation of pulmonary artery smooth muscle cells. Therefore, the mesoporous selenium nanoparticles described in this invention can not only be used as a drug to inhibit the proliferation of pulmonary artery smooth muscle cells, but also as a carrier for the drug to inhibit the proliferation of pulmonary artery smooth muscle cells.

[0011] Preferably, the surfactant mentioned in step (1) is CTAB.

[0012] Preferably, in step (1), the ratio of surfactant to water is 100 mg: 40-50 mL.

[0013] Most preferably, the ratio of surfactant to water in step (1) is 100 mg: 46 mL.

[0014] Preferably, the Na2SeO3 solution mentioned in step (2) refers to a Na2SeO3 solution with a concentration of 4 to 6 mM.

[0015] Most preferably, the Na2SeO3 solution mentioned in step (2) refers to a Na2SeO3 solution with a concentration of 5 mM.

[0016] Preferably, the VC solution mentioned in step (2) refers to a VC solution with a concentration of 15 to 25 mM.

[0017] Most preferably, the VC solution mentioned in step (2) refers to a VC solution with a concentration of 20 mM.

[0018] The present invention also provides a mesoporous selenium nanoparticle prepared by the above method.

[0019] This invention also provides a method for preparing a mesoporous nano-selenium drug-carrying system, comprising the following steps:

[0020] Mesoporous selenium nanoparticles were added to a mixture containing EGCG and stirred for 40–90 min. After stirring, the solid was separated to obtain MSeNPs / EGCG, which is the mesoporous selenium nanoparticle drug delivery system.

[0021] The inventors made a surprising discovery in numerous experiments that the mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by loading EGCG onto mesoporous selenium nanoparticles can significantly enhance the inhibitory effect of EGCG on pulmonary artery smooth muscle cell proliferation; at the same time, its inhibitory effect on pulmonary artery smooth muscle cell proliferation is significantly higher than that of EGCG alone or mesoporous selenium nanoparticles alone. This indicates that the mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by loading EGCG onto mesoporous selenium nanoparticles can produce a synergistic inhibitory effect on pulmonary artery smooth muscle cell proliferation.

[0022] Preferably, the ratio of mesoporous nano-selenium to the mixed solution is 1-2 mg: 1-2 mL.

[0023] Most preferably, the ratio of mesoporous nano-selenium to the mixed solution is 1 mg: 1 mL.

[0024] Preferably, the EGCG content in the mixture is 1 mg / mL.

[0025] Preferably, the preparation method of the mesoporous nano-selenium drug-carrying system includes the following steps:

[0026] Mesoporous selenium nanoparticles were added to a mixture containing EGCG and CAR and stirred for 40–90 min. After stirring, the solid was separated to obtain MSeNPs / EGCG / CAR, which is the mesoporous selenium nanoparticle drug delivery system.

[0027] Further research by the inventors revealed a surprising discovery: the mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG), prepared by loading EGCG with mesoporous selenium nanoparticles, and then further modified with CAR to obtain the mesoporous selenium nanoparticle drug-loaded system MSeNPs / EGCG / CAR, can further enhance the inhibitory effect of the mesoporous selenium nanoparticle drug-loaded system on pulmonary artery smooth muscle cell proliferation. Its inhibitory effect on pulmonary artery smooth muscle cell proliferation is significantly higher than that of mesoporous selenium nanoparticles alone, EGCG alone, or MSeNPs / EGCG.

[0028] Preferably, the ratio of mesoporous nano-selenium to the mixed solution is 1-2 mg: 1-2 mL.

[0029] Most preferably, the ratio of mesoporous selenium nanoparticles to the mixture containing EGCG is 1 mg: 1 mL.

[0030] Preferably, the EGCG content in the mixture is 1 mg / mL; the CAR content in the mixture is 2.5 mM.

[0031] This invention provides a mesoporous nano-selenium drug-loaded system prepared by the above preparation method.

[0032] The present invention also provides the application of the above-mentioned mesoporous selenium nanoparticles in the preparation of a drug having the effect of inhibiting the proliferation of pulmonary artery smooth muscle cells, or in the use of a carrier for preparing a drug having the effect of inhibiting the proliferation of pulmonary artery smooth muscle cells.

[0033] The present invention also provides the application of the above-mentioned mesoporous selenium nanoparticles in the preparation of a drug having the effect of treating pulmonary hypertension, or in the preparation of a carrier for a drug having the effect of treating pulmonary hypertension.

[0034] The present invention also provides the application of the above-mentioned mesoporous nano-selenium drug-carrying system in the preparation of drugs that inhibit the proliferation of pulmonary artery smooth muscle cells, or in the preparation of drugs that treat pulmonary hypertension.

[0035] Beneficial effects:

[0036] (1) The present invention provides a novel method for preparing mesoporous selenium nanoparticles, and studies have shown that they have a certain inhibitory effect on the proliferation of pulmonary artery smooth muscle cells. Therefore, the mesoporous selenium nanoparticles described in the present invention can not only be used as a drug to inhibit the proliferation of pulmonary artery smooth muscle cells, but also as a carrier for the drug to inhibit the proliferation of pulmonary artery smooth muscle cells.

[0037] (2) Further research found that the mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by loading EGCG with mesoporous selenium nanoparticles can significantly enhance the inhibitory effect of EGCG on pulmonary artery smooth muscle cell proliferation; the mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by loading EGCG with mesoporous selenium nanoparticles can be further modified with CAR to obtain the mesoporous selenium nanoparticle drug-loaded system MSeNPs / EGCG / CAR, which can further enhance the inhibitory effect of mesoporous selenium nanoparticle drug-loaded system on pulmonary artery smooth muscle cell proliferation.

[0038] (3) The mesoporous nano-selenium drug delivery system MSeNPs / EGCG / CAR described in this invention can not only effectively deliver target drugs and functionalized nanoparticles to the target site, maximizing drug delivery efficiency and causing less tissue damage, but also achieve multi-target and multi-mechanism treatment of pulmonary hypertension by taking advantage of the superior bioactivity of nanomaterials.

[0039] (4) The mesoporous nano-selenium drug delivery system MSeNPs / EGCG / CAR described in this invention can increase cell absorption and enable the drug to target the hypertensive pulmonary artery, thereby improving the instability and side effects of traditional PAH treatment drugs.

[0040] (3) The mesoporous nano-selenium drug delivery system MSeNPs / EGCG / CAR described in this invention has potential application value for the treatment of vascular diseases, including pulmonary hypertension, atherosclerosis and tumors, and opens up new ideas for PAH drug design. Attached Figure Description

[0041] Figure 1 This is a model diagram of a mesoporous nano-selenium drug delivery system (MSeNPs / EGCG / CAR).

[0042] Figure 2 This is a flowchart of the synthesis of mesoporous nano-selenium drug delivery system (MSeNPs / EGCG / CAR).

[0043] Figure 3 Characterization of the mesoporous nano-selenium drug-carrying system: A, B. Transmission electron microscopy (TEM) images; C. EDX elemental analysis; D. Hydrodynamic particle size distribution; E. Nitrogen adsorption-desorption isotherms.

[0044] Figure 4 The effects of mesoporous selenium nanoparticles and their various components on PASMC cell proliferation are: A. MTS; B. WB; C. EDU.

[0045] Figure 5 MSeNPs / EGCG / CAR inhibit PASMC migration.

[0046] Figure 6 MSeNPs / EGCG / CAR inhibits the single-cell motility of PASMCs.

[0047] Figure 7 MSeNPs / EGCG / CAR promote apoptosis in PASMCs.

[0048] Figure 8 The effects of MSeNPs / EGCG / CAR on right ventricular pressure and right ventricular hypertrophy in hypoxia-induced PAH mice / rats.

[0049] Figure 9 This study investigated the effects of MSeNPs / EGCG / CAR on pulmonary vascular remodeling in hypoxia-induced PAH mice / rats. A. HE staining and α-SMA staining of mouse lung tissue; B. HE staining and α-SMA staining of rat lung tissue. Detailed Implementation

[0050] The present invention will be further explained below with reference to specific embodiments, but the embodiments do not limit the present invention in any way.

[0051] The drug EGCG in the following examples has the following structural formula:

[0052]

[0053] The CAR in the following examples has the following amino acid sequence: CARSKNKDC, and its structural formula is as follows. It is a cyclic short peptide composed of 9 amino acids.

[0054]

[0055] Example 1: Preparation of mesoporous selenium nanoparticles

[0056] First, dissolve 100 mg CTAB in 46 mL of water at room temperature for about 30 min, then add 30 mg Zn to the solution and stir at 800 rpm for 12 h.

[0057] Next, add 2 mL of 5 mM Na2SeO3 aqueous solution and 2 mL of 20 mM VC aqueous solution, and continue stirring for 2 h (pH 8.0);

[0058] Next, the obtained sample was dispersed in 30 mL of ethanol, and the dispersion was stirred (800 rpm, 80 °C) and refluxed for 24 h to remove the surfactant CTAB.

[0059] Finally, the solution was centrifuged and washed three times with water, and then freeze-dried to obtain MSeNPs nanoparticles, namely the mesoporous selenium nanoparticles.

[0060] Example 2: Preparation of mesoporous nano-selenium drug delivery system (MSeNPs / EGCG)

[0061] 250 mg of mesoporous selenium nanoparticles (MSeNPs) prepared according to the method in Example 1 were added to 250 mL of a mixed aqueous solution containing EGCG (concentration: 1 mg / mL) and gently stirred (300 rpm) for 1 h to load EGCG onto the surface of the selenium nanoparticles. Subsequently, the mixed solution was centrifuged three times at 600 rpm to obtain the purified MSeNPs / EGCG, which is the mesoporous selenium nanoparticle drug-loaded system.

[0062] Example 3: Preparation of mesoporous nano-selenium drug delivery system (MSeNPs / EGCG)

[0063] 250 mg of mesoporous selenium nanoparticles (MSeNPs) prepared according to the method in Example 1 were added to 250 mL of a mixed aqueous solution containing EGCG (concentration: 1 mg / mL) and CAR (concentration: 2.5 mM) and gently stirred (300 rpm) for 1 h to load EGCG onto the surface of the selenium nanoparticles. Subsequently, the mixed solution was centrifuged three times at 600 rpm to obtain the purified MSeNPs / EGCG / CAR, which is the mesoporous selenium nanoparticle drug delivery system.

[0064] Figure 3 This is a characterization diagram of the mesoporous selenium nanoparticle drug delivery system. (From...) Figure 3 It can be seen that the particle size of unloaded drug-containing nanoparticles (MSeNPs) is approximately 50 nm, while the average particle size of EGCG and CAR-loaded nanoparticles (MSeNPs / EGCG / CAR) is approximately 100 nm. Figure 3 A, B); Elemental analysis results show that the main component of mesoporous nano-selenium is Se( Figure 3 C); The results of fluid dynamic particle size distribution detection are consistent with the TEM results. Figure 3 D). Evaluating the sealing efficiency of nanosystems, such as... Figure 3 As shown in Figure E, the adsorption-desorption curves of MSeNPs increased significantly between 0.2 and 0.4, indicating that MSeNPs are mesoporous nanoparticles. The addition of EGCG and CAR slowed down the increase in the curves, indicating that EGCG and CAR filled the mesopores of MSeNPs and were loaded on the surface of MSeNPs.

[0065] Example 1: MSeNPs / EGCG / CAR inhibits excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) in vitro.

[0066] (1) Effects of MSeNPs / EGCG / CAR on the proliferation capacity of PASMCs

[0067] Excessive proliferation of PASMCs is an important cellular mechanism leading to pulmonary artery vascular remodeling. To investigate the effect of MSeNPs / EGCG / CAR on PASMC proliferation, this invention used the MTS method to detect the effect of each component of the mesoporous selenium nanoparticle drug delivery system on PASMC cell proliferation, with all drug concentrations at 2 μM.

[0068] The results show that: Figure 4 This refers to the effects of each component of the mesoporous selenium nanoparticle drug delivery system on the proliferation of PASMCs. For example... Figure 4 As shown in Figure A, the results indicate that MSeNPs and EGCG alone can inhibit the proliferation of PASMCs cells to a small extent, with inhibition rates of 14% and 29%, respectively. MSeNPs loaded with EGCG can increase the inhibitory effect to 44%. The CAR-modified nano-drug delivery system MSeNPs / EGCG / CAR has the best inhibitory effect on PASMCs cell proliferation, reaching an inhibition rate of 62%.

[0069] The above results demonstrate that the mesoporous selenium nanoparticles prepared by the method described in this invention possess a certain inhibitory effect on pulmonary artery smooth muscle cell proliferation. The mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by loading EGCG onto mesoporous selenium nanoparticles significantly enhances the inhibitory effect of EGCG on pulmonary artery smooth muscle cell proliferation; furthermore, its inhibitory effect on pulmonary artery smooth muscle cell proliferation is significantly higher than that of EGCG alone or mesoporous selenium nanoparticles alone. This also indicates that the mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by loading EGCG onto mesoporous selenium nanoparticles can produce a synergistic inhibitory effect on pulmonary artery smooth muscle cell proliferation. The mesoporous selenium nanoparticle drug-loaded system (MSeNPs / EGCG) prepared by further modifying it with CAR, resulting in the mesoporous selenium nanoparticle drug-loaded system MSeNPs / EGCG / CAR, can further enhance the inhibitory effect on pulmonary artery smooth muscle cell proliferation.

[0070] MSeNPs, MSeNPs / EGCG, and MSeNPs / EGCG / CAR were selected and detected using Western blotting to detect the proliferation protein PCNA. The results are as follows: Figure 4B, MSeNPs / EGCG / CAR significantly inhibited PCNA protein, confirming its effective inhibition of PASMC cell proliferation. EDU results were consistent with MTS and WB results. Figure 4 C). In summary, it can be demonstrated that MSeNPs / EGCG / CAR can inhibit the proliferation of PASMCs cells.

[0071] (2) The impact of MSeNPs / EGCG / CAR on the migration ability of PASMCs

[0072] Enhanced migration ability of PASMCs is an important factor in pulmonary artery vascular remodeling during the pathogenesis of PAH. The effect of MSeNPs / EGCG / CAR on PASMC migration ability was observed and analyzed using a scratch assay.

[0073] The results show that: Figure 5 MSeNPs / EGCG / CAR inhibit PASMC migration. For example... Figure 5 As shown in A and B, the scratch assay results indicate that MSeNPs / EGCG / CAR significantly inhibits the migration ability of PASMCs. This invention also analyzed the effect of MSeNPs / EGCG / CAR on the single-cell movement trajectory of PASMCs. Figure 6 The results showed that MSeNPs / EGCG / CAR significantly inhibited single-cell motility in PASMCs.

[0074] (3) Effects of MSeNPs / EGCG / CAR on PASMC apoptosis

[0075] Apoptosis imbalance in PASMCs is one of the important cellular mechanisms leading to pulmonary artery vascular remodeling. Previous experiments in this invention used Annexin V / PI double staining to detect the effect of MSeNPs / EGCG / CAR on PASMC cell apoptosis.

[0076] The results show that: Figure 7 MSeNPs / EGCG / CAR promote apoptosis in PASMCs. For example... Figure 7 As shown, MSeNPs / EGCG / CAR can promote apoptosis of PASMCs. Hypoxia-induced abnormal proliferation, excessive migration, and apoptosis imbalance in PASMCs lead to pulmonary arteriolar remodeling, and these pathological changes are key factors in the increased pulmonary vascular resistance during the pathogenesis of pulmonary hypertension. Previous experimental results of this invention confirm that MSeNPs / EGCG / CAR can inhibit abnormal proliferation and excessive migration of PASMCs and promote apoptosis of PASMCs.

[0077] Experimental Example 2: Effect of MSeNPs / EGCG / CAR on Pulmonary Hypertension in Vivo

[0078] (1) Effects of MSeNPs / EGCG / CAR on right ventricular pressure and right ventricular hypertrophy in hypoxia-induced PAH rats

[0079] To investigate the role of MSeNPs / EGCG / CAR in the development of PAH, right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index [RV / (LV+S)] were measured in mice / rats after 4 weeks of chronic hypoxia treatment. Mice / rats were weighed, anesthetized with prepared aphthylamine (concentration, 0.6 mL / 40 g, intraperitoneal injection), and fixed in a supine position. An incision was made in the skin at the right external jugular vein, and the right external jugular vein was dissected. The distal end of the external jugular vein was ligated, and a small incision was made proximal to the external jugular vein using ophthalmic scissors. A PE tube filled with heparin sodium solution was inserted through the small incision, passing through the right external jugular vein, superior vena cava, and right atrium to the right ventricle. The other end of the catheter was connected to a pressure sensor, and changes in right ventricular systolic pressure (RVSP) were recorded using a physiological signal recording and analysis system.

[0080] After the initial experiments, the heart was dissected, and the major blood vessels, right atrium, and left atrium connected to the heart were removed. The right ventricle (RV) and left ventricle plus interventricular septum (LV+S) were separated. The fluid on the surface of the heart was blotted dry with filter paper, and the hearts were weighed separately. The weights of the right ventricle and the left ventricle plus interventricular septum were recorded. The ratio of the weight of the right ventricle to the weight of the left ventricle plus interventricular septum [RV / (LV+S)] was calculated. [RV / (LV+S)] was used as an indicator to evaluate the degree of right ventricular hypertrophy.

[0081] The results show that: Figure 8 This study investigated the effects of MSeNPs / EGCG / CAR on right ventricular pressure and right ventricular hypertrophy in hypoxia-induced PAH mice / rats. The experimental results are as follows: Figure 8 As shown in A / C, compared with the normoxic control group, the RVSP of wild-type hypoxic mice / rats was significantly increased. Although the RVSP of hypoxic mice / rats also increased after MSeNPs / EGCG / CAR administration, it was significantly lower than that of the wild-type hypoxic group. The right ventricular hypertrophy index results showed ( Figure 8 Chronic hypoxia treatment induced significant compensatory hypertrophy of the right ventricle in mice / rats (B / D). The right ventricular hypertrophy index was significantly lower in mice / rats treated with MSeNPs / EGCG / CAR compared to wild-type mice. These results indicate that MSeNPs / EGCG / CAR can inhibit the development of hypoxia-induced PAH.

[0082] (2) Effects of MSeNPs / EGCG / CAR on hypoxia-induced pulmonary vascular remodeling in PAH rats

[0083] To further investigate the role of MSeNPs / EGCG / CAR in pulmonary arterial vascular remodeling induced by chronic hypoxia, HE staining of mouse / rat lung tissue was performed. Figure 9A) and α-SMA immunofluorescence staining ( Figure 9 B). Immunohistochemical staining of paraffin sections of mouse / rat lung tissue was performed using α-SMA antibody, PCNA antibody, and CD31 antibody. α-actin (α-SMA) is a marker protein for smooth muscle cells. The expression of α-SMA in the pulmonary arteries of each group of mice was measured using optical density values ​​to determine the proliferation of smooth muscle cells in the pulmonary artery media.

[0084] The results show that: Figure 9 This study investigated the effect of MSeNPs / EGCG / CAR on pulmonary vascular remodeling in hypoxia-induced PAH mice / rats. The results indicate that MSeNPs / EGCG / CAR can inhibit pulmonary artery vascular remodeling induced by chronic hypoxia in mice / rats.

[0085] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A method for preparing mesoporous nano-selenium, characterized in that: The following steps are included: (1) dissolving a surfactant in water, then adding Zn and stirring to obtain a mixed solution; (2) Then, Na2SeO3 solution and VC solution are added to the mixed solution and stirred for reaction; (3) After the reaction is completed, the solid is separated and added to ethanol for heating and reflux for 20 to 30 hours. After the reflux is completed, the solid is taken out and dried to obtain nanoparticles MSeNPs, i.e., the mesoporous nano-selenium.

2. The preparation method according to claim 1, characterized in that: The ratio of surfactant to water in step (1) is 100 mg: 40-50 mL; Most preferably, the ratio of surfactant to water in step (1) is 100 mg:46 mL.

3. The preparation method according to claim 1, characterized in that: The Na2SeO3 solution described in step (2) refers to a Na2SeO3 solution with a concentration of 4 to 6 mM; Most preferably, the Na2SeO3 solution described in step (2) refers to a Na2SeO3 solution with a concentration of 5 mM. The VC solution described in step (2) refers to a VC solution with a concentration of 15 to 25 mM. Most preferably, the VC solution in step (2) refers to a VC solution with a concentration of 20 mM.

4. Mesoporous nano-selenium prepared by the method according to any one of claims 1 to 3.

5. A method for preparing a mesoporous nano-selenium drug delivery system, characterized in that: The following steps are included: The mesoporous nano-selenium is added into the mixed solution containing EGCG and stirred for 40 to 90 minutes. After the stirring is completed, the solid is separated to obtain MSeNPs / EGCG, that is, the mesoporous nano-selenium drug delivery system.

6. The method for preparing the mesoporous nano-selenium drug delivery system according to claim 5, characterized in that: The following steps are included: Mesoporous nano-selenium is added into the mixed solution containing EGCG and CAR, and stirred for 40 to 90 minutes; after stirring, the solid is separated to obtain MSeNPs / EGCG / CAR, i.e., the mesoporous nano-selenium drug delivery system.

7. The mesoporous nano-selenium drug delivery system prepared by the preparation method according to claim 5 or 6.

8. Use of the mesoporous nano-selenium according to claim 4 in preparing a drug having an effect of inhibiting the proliferation of pulmonary arterial smooth muscle cells, or in preparing a carrier of a drug having an effect of inhibiting the proliferation of pulmonary arterial smooth muscle cells.

9. Use of the mesoporous nano-selenium according to claim 4 in preparing a drug for treating pulmonary hypertension, or in preparing a carrier for a drug for treating pulmonary hypertension.

10. Use of the mesoporous nano-selenium drug-carrying system according to claim 7 in preparing a drug having an effect of inhibiting the proliferation of pulmonary arterial smooth muscle cells, or in preparing a drug having an effect of treating pulmonary hypertension.

Images